Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $238.53 million. The enterprise value is $215.77 million.
| Market Cap | 238.53M |
| Enterprise Value | 215.77M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 63.36 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Current Share Class | 63.36M |
| Shares Outstanding | 63.36M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 6.39% |
| Owned by Institutions (%) | 18.83% |
| Float | 29.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.28 |
| Forward PS | 5,388.92 |
| PB Ratio | 7.50 |
| P/TBV Ratio | 7.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.58.
| Current Ratio | 2.76 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -121.66% and return on invested capital (ROIC) is -60.28%.
| Return on Equity (ROE) | -121.66% |
| Return on Assets (ROA) | -51.94% |
| Return on Invested Capital (ROIC) | -60.28% |
| Return on Capital Employed (ROCE) | -179.76% |
| Weighted Average Cost of Capital (WACC) | 10.69% |
| Revenue Per Employee | $247,464 |
| Profits Per Employee | -$1.46M |
| Employee Count | 56 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pyxis Oncology has paid $1.39 million in taxes.
| Income Tax | 1.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +256.60% in the last 52 weeks. The beta is 1.32, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +256.60% |
| 50-Day Moving Average | 2.43 |
| 200-Day Moving Average | 2.34 |
| Relative Strength Index (RSI) | 71.95 |
| Average Volume (20 Days) | 954,928 |
Short Selling Information
The latest short interest is 3.25 million, so 5.14% of the outstanding shares have been sold short.
| Short Interest | 3.25M |
| Short Previous Month | 2.29M |
| Short % of Shares Out | 5.14% |
| Short % of Float | 11.20% |
| Short Ratio (days to cover) | 2.26 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $13.86 million and -$81.74 million in losses. Loss per share was -$1.30.
| Revenue | 13.86M |
| Gross Profit | 11.47M |
| Operating Income | -83.18M |
| Pretax Income | -80.35M |
| Net Income | -81.74M |
| EBITDA | -81.45M |
| EBIT | -85.87M |
| Loss Per Share | -$1.30 |
Balance Sheet
The company has $41.02 million in cash and $18.26 million in debt, with a net cash position of $22.76 million or $0.36 per share.
| Cash & Cash Equivalents | 41.02M |
| Total Debt | 18.26M |
| Net Cash | 22.76M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 31.27M |
| Book Value Per Share | 0.50 |
| Working Capital | 29.04M |
Cash Flow
In the last 12 months, operating cash flow was -$66.97 million and capital expenditures -$9,000, giving a free cash flow of -$66.98 million.
| Operating Cash Flow | -66.97M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 4.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -66.98M |
| FCF Per Share | -$1.06 |
Margins
| Gross Margin | 82.77% |
| Operating Margin | -600.19% |
| Pretax Margin | -579.80% |
| Profit Margin | n/a |
| EBITDA Margin | -587.73% |
| EBIT Margin | -619.61% |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.06% |
| Shareholder Yield | -3.06% |
| Earnings Yield | -34.13% |
| FCF Yield | -27.97% |
Analyst Forecast
The average price target for Pyxis Oncology is $7.33, which is 94.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.33 |
| Price Target Difference | 94.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -3.96% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -11.51 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.51 |
| Piotroski F-Score | 1 |